<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Drug Resistance In Cancer: Mechanisms and Overcoming Strategies

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorAslam, Muhammad Jawad
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentHalasi, Barbara Dóra
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Igazságügyi Orvostani Intézet
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.date.accessioned2026-07-02T10:54:23Z
dc.date.available2026-07-02T10:54:23Z
dc.date.created2026-05-28
dc.description.abstractTumors develop resistance to therapy through multiple adaptive mechanisms, including drug efflux pumps, enhanced DNA repair, activation of pro-survival pathways, targeted molecule alterations, enzymatic detoxification mechanisms, tumor heterogeneity, and cancer stem cell formation. They also modify the tumor micro-environment to support survival, growth, and metastasis; contributing to the high mortality associated with advanced cancers. To overcome resistance, strategies such as immunotherapy, epigenetic therapies, gene editing, anti-angiogenic drugs, nano-medicine based drug delivery, synthetic lethality approaches (e.g. PARP inhibitors for BRCA-mutated cancers), personalized medicine, dietary interventions, and combination therapies are being developed, showing promising results in reducing the emergence of drug resistant cancer.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent92
dc.identifier.urihttps://hdl.handle.net/2437/412630
dc.language.isoen
dc.rights.infoHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectDrug resistance
dc.subjectmultidrug resistance (MDR)
dc.subjectintrinsic resistance
dc.subjectacquired resistance
dc.subjectcross-resistance
dc.subjecttherapeutic escape
dc.subjectCancer stem cells (CSCs)
dc.subjectepithelial-to-mesenchymal transition (EMT)
dc.subjectpartial EMT (pEMT)
dc.subjectepithelial-mesenchymal plasticity (EMP)
dc.subjectphenotypic stabilizing factors (PSFs)
dc.subjectMuller's Ratchet
dc.subjecttumor heterogeneity
dc.subjectself-renewal
dc.subjectquiescence
dc.subjectABC transporters
dc.subjectP-glycoprotein (P-gp/ABCB1)
dc.subjectbreast cancer resistance protein (BCRP/ABCG2)
dc.subjectmultidrug resistance-associated protein 1 (MRP1/ABCC1)
dc.subjectvault proteins
dc.subjectmajor vault protein (MVP/LRP)
dc.subjectRLIP76
dc.subjectefflux pump inhibitors
dc.subjectEnzymatic Detoxification
dc.subjectGlutathione S-transferase (GST)
dc.subjectGSTP1
dc.subjectglutathione (GSH)
dc.subjectUDP-glucuronosyltransferase (UGT)
dc.subjectaldehyde dehydrogenase (ALDH)
dc.subjectNQO1
dc.subjectcytochrome P450 (CYP450)
dc.subjectNrf2
dc.subjectKEAP1
dc.subjectreactive oxygen species (ROS)
dc.subjectGatekeeper mutations
dc.subjectT790M
dc.subjectBCR-ABL
dc.subjectEGFR
dc.subjectgene amplification
dc.subjectHER2
dc.subjectalternative splicing
dc.subjectpost-translational modifications
dc.subjectPROTACs
dc.subjectliquid biopsy
dc.subjectctDNA
dc.subjectBcl-2 family
dc.subjectBH3 mimetics
dc.subjectinhibitors of apoptosis proteins (IAPs)
dc.subjectSMAC/Diablo
dc.subjectTRAIL
dc.subjectdecoy receptors (DcR1/DcR2/DcR3)
dc.subjectc-FLIP
dc.subjectFADD
dc.subjectcaspase
dc.subjectcytochrome c
dc.subjectautophagy
dc.subjectBeclin-1
dc.subjectTumor microenvironment (TME)
dc.subjecthypoxia
dc.subjectHIF-1α
dc.subjectWarburg effect
dc.subjectangiogenesis
dc.subjectVEGF
dc.subjectcancer-associated fibroblasts (CAFs)
dc.subjecttumor exosomes
dc.subjectmyeloid-derived suppressor cells (MDSCs)
dc.subjectT regulatory cells (Tregs)
dc.subjectPD-1
dc.subjectPD-L1
dc.subjectimmune checkpoint inhibitors
dc.subjectimmunosuppression
dc.subjectextracellular matrix (ECM)
dc.subjectEpigenetics
dc.subjectDNA methylation
dc.subjectDNMT inhibitors
dc.subjecthistone deacetylase (HDAC)
dc.subjectHDAC inhibitors
dc.subjectBET proteins
dc.subjectBRD4
dc.subjectSWI/SNF
dc.subjectncRNA
dc.subjectmiRNA
dc.subjectlncRNA
dc.subjectcircRNA
dc.subjectepitranscriptomics
dc.subjectdrug-tolerant persister cells
dc.subjectCRISPR
dc.subjectprime editing
dc.subjectbase editing
dc.subjectmultiplex CRISPR
dc.subjectantibody-drug conjugates (ADCs)
dc.subjectsynthetic lethality
dc.subjectPARP inhibitors
dc.subjectBRCA1/2
dc.subjectATR-CHK1-WEE1 axis
dc.subjectCAR-T cell therapy
dc.subjectnano-medicine
dc.subjectketogenic diet
dc.subjectartificial intelligence
dc.subjectpersonalised medicine
dc.subject.dspaceMedicine::Oncology
dc.titleDrug Resistance In Cancer: Mechanisms and Overcoming Strategies

Fájlok

Eredeti köteg (ORIGINAL bundle)

Megjelenítve 1 - 1 (Összesen 1)
Bélyegkép
Név:
Thesis.pdf
Méret:
6,03 MB
Formátum:
Adobe Portable Document Format
Letöltés

Engedélyek köteg

Megjelenítve 1 - 1 (Összesen 1)
Bélyegkép
Név:
license.txt
Méret:
1,94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés

Gyűjtemények

Theses (Faculty of Medicine)